Ironwood Pharmaceuticals and Allergan have entered an agreement with Mylan Pharmaceuticals to settle patent litigations over generic versions of Linzess (linaclotide) medicine.

Linaclotide is a guanylate cyclase‐C (GC‐C) agonist marketed by Ironwood and Allergan in the US under the brand name Linzess to treat irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The litigation was initiated in response to Mylan’s abbreviated new drug applications (ANDAs) filing before the expiration of Ironwood and Allergan’s applicable patents.

Under the terms of the settlement agreement, Mylan gains a licence from Ironwood and Allergan to market a generic version of 145mcg and 290mcg Linzess in the US from 5 February 2030.

“As a result of the settlement, all ongoing Hatch-Waxman litigations between the companies and Mylan regarding Linzess patents pending in the US District Court for the Northern District of West Virginia will be dismissed.”

The generic of 72mcg dosage of the drug could be marketed in the country from 5 August 2030.

Ironwood Pharmaceuticals in a statement said: “As a result of the settlement, all ongoing Hatch-Waxman litigations between the companies and Mylan regarding Linzess patents pending in the US District Court for the Northern District of West Virginia will be dismissed.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This settlement is the third Linzess patent infringement settlement reached between Ironwood and Allergan. In January last year, the companies signed an agreement with Sun Pharmaceutical Industries’ wholly owned subsidiaries to resolve a similar litigation.

Additional litigations related to ANDAs for generic versions of the drug are pending in the US District Court for the District of Delaware.

Besides the US, linaclotide is marketed in Europe as Constella for adults with moderate to severe IBS-C.

Ironwood’s partner Astellas markets Linzess to treat adults with IBS-C in Japan. Ironwood further collaborated with AstraZeneca to develop and commercialise linaclotide in China, Hong Kong and Macau.

Ironwood and Allergan are responsible for development and commercialisation activities of the drug in all other global territories.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact